Ovarian Cancer

Olvimulogene nanivacirepvec, an oncolytic viral-based therapy, has earned a fast track designation from the FDA in ovarian cancer resistant or refractory to platinum-based chemotherapy.

During a Targeted Oncology™ Case-Based Roundtable™ event, Robert Holloway, MD, explored the state of PARP inhibitors for patients with advanced ovarian cancer including the PRIMA trial of niraparib.

The combination of tumor-infiltrating lymphocytes and chemotherapy showed a robust response rate and improvements in progression-free survival in a phase 1/2 study.

Findings from a phase 1 trial shows the early promise of an ENB-003 and pembrolizumab regimen for the treatment of platinum refractory or resistant ovarian cancer.

Findings from the phase 2 RAMP 201 trial show avutometinib plus defactinib demonstrates robust efficacy in patients with recurrent low-grade serious ovarian cancer.

Retrospective data shows that a multidisciplinary surgical approach may improve survival in patients with ovarian cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, David M. O'Malley, MD, discussed with participants their experiences with using PARP inhibitors in patients with advanced ovarian cancer.

The OPEB-01 trial showed a potential maintenance role for olaparib, pembrolizumab, and bevacizumab in patients who responded to chemotherapy after platinum-sensitive recurrence to ovarian cancer.

The phase 3 FLAMES trial results demonstrated an improvement in progression-free survival with senaparib monotherapy vs placebo, regardless of patient subgroup, in patients with newly diagnosed, advanced ovarian cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Leslie M. Randall, MD, MAS, evaluated the outcomes of the PRIMA/ENGOT-OV26/GOG-3012 study of niraparib as primary maintenance therapy for patients with ovarian cancer.

The addition of PARP inhibitors for the treatment of patients with BRCA-mutated advanced ovarian cancer has provided clinicians with a stronger set of treatment options. Looking at how the BRCA mutation responds to these inhibitors is then vital to deciding the patient’s treatment path.

The fast track designation for AVB-001 granted by the FDA recognizes its potential as a treatment option for patients with relapsed/refractory ovarian cancer.

Results of the phase 3 MIRASOL study evaluating mirvetuximab soravtansine for platinum-resistant ovarian cancer will be announced at an upcoming meeting.

Findings from a phase 1 support the fast track designation given by the FDA to IDE161, a potent, selective, small-molecule inhibitor of PARG, for patients with BRCA1/2 mutant ovarian cancer.

In an interview Targeted Oncology, Christina Fotopoulou, MD, PhD, discussed the background and results of 3 studies for patients with ovarian cancer.

The primary end point was not met in the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial of tumor treating fields therapy plus paclitaxel in patients with platinum-resistant ovarian cancer.

Barbara Buttin, MD, discusses the PAOLA-1 clinical trial and it impact on the first-line treatment of ovarian cancer.

Chad A. Hamilton, MD, offers closing thoughts on the future outlook and unmet needs in the ovarian cancer treatment landscape.

Key takeaways from recent data updates from the PRIMA and PAOLA-1 trials investigating PARP inhibitors in ovarian cancer.

Chad A. Hamilton, MD, shares strategies for managing gastrointestinal toxicities and fatigue for patients receiving PARP inhibitors for the treatment of ovarian cancer.

Clinical insights on adverse effects seen with PARP inhibitors in the treatment of patients with ovarian cancer.

An overview of factors that influence the initiation of maintenance therapy for patients with ovarian cancer.

Chad A. Hamilton, MD, discusses how clinical trial data inform treatment selection for patients with ovarian cancer.

A comprehensive overview of the maintenance therapy landscape in ovarian cancer, with a focus on clinical trials investigating bevacizumab, olaparib, and niraparib.